Table 1.
Patient characteristics
| ID | Assays | Diagnosis | FVC | FEV1 | Dyspnea | Sex | Age | Ethnicity | Source | Echo/CT |
|---|---|---|---|---|---|---|---|---|---|---|
| MVECs used in the control group | ||||||||||
| Ctrl01 | PCR, RNA-seq, IF, ELISA, ECIS | NSCLC, adenocarcinoma | – | – | No | F | 55 | Caucasian | Lob | No dilation of RV, RA, or LV |
| Ctrl02 | PCR, RNA-seq, IF, ELISA | NSCLC, squamous cell carcinoma | 3.11 (100%) | 2.31 (98%) | No | M | 79 | Caucasian | Lob | No dilation of RV, RA, or LV |
| Ctrl03 | PCR, RNA-seq, IF, ECIS | NSCLC | 5.3 (96%) | 4.39 (98%) | No | M | 42 | Caucasian | Lob | No dilation of RV, RA, or LV |
| Ctrl04 | IF, ELISA, ECIS | NSCLC | 4.13 (110%) | 3.23 (110%) | No | F | 60 | Caucasian | Lob | No dilation of RV, RA, or LV |
| Ctrl05 | PCR, RNA-seq, ECIS | NSCLC, squamous cell carcinoma | 2.75 (100%) | 1.17 (50%) | No | F | 61 | Caucasian | Lob | No dilation of RV, RA, or LV |
| Ctrl06 | PCR, RNA-seq | Tumoral obstruction | – | – | Yes | M | 42 | Caucasian | Lob | Enlarged RV, small LV, enlarged RA |
| ID | Assays | Diagnosis | mPAP | PVR | CI | Sex | Age | Ethnicity | Source | Treatment |
|---|---|---|---|---|---|---|---|---|---|---|
| MVECs used in the PAH group | ||||||||||
| PAH01 | PCR, RNA-seq, ELISA | iPAH | 54 | – | 2.1 | F | 54 | Caucasian | Obd | PDE5-I, ERA, PGI2 |
| PAH02 | PCR, RNA-seq, IF, ELISA, ECIS | hPAH (BMPR2) | 68 | – | 1.6 | F | 40 | Caucasian | Ltx | PDE5-I, ERA, PGI2 |
| PAH03 | PCR, RNA-seq, ELISA, ECIS | iPAH | 43 | 620 | 2.1 | F | 42 | Caucasian | Ltx | PDE5-I, PGI2 |
| PAH04 | PCR, RNA-seq, IF, ELISA, ECIS | iPAH | 89 | 1527 | 1.9 | F | 22 | Caucasian | Ltx | PDE5-I, ERA, PGI2 |
| PAH05 | PCR, RNA-seq, IF, ELISA, ECIS | iPAH | 102 | 1375 | 3.4 | M | 21 | Caucasian | Ltx | PDE5-I, ERA, PGI2 |
ECIS barrier function, IF immunofluorescence, MVECs lung microvascular endothelial cells, NSCLC non-small-cell lung carcinoma, FVC forced vital capacity (L), FEV1 first second of forced expiration (L), Lob lobectomy, RV right ventricle, RA right atrium, LV left ventricle, iPAH idiopathic pulmonary arterial hypertension, hPAH hereditary PAH, mPAP mean pulmonary artery pressure (mmHg), PVR pulmonary vascular resistance (WU), CI cardiac index (L/min/m2), PDE5-I phosphodiesterase type 5 inhibitor, PGI2 prostacyclin, ERA endothelin receptor antagonist, Obd autopsy, Ltx lung transplantation. PAH patients hemodynamics were determined by right heart catheterization before lung transplantation